Helsinn: Mary Lynne Hedley appointed to board of directors

Helsinn – the Swiss pharmaceutical group focused on building quality cancer care and rare disease products – is pleased to announce the appointment of Mary Lynne Hedley as a new member of its board of directors, effective April 28, 2021.

Hedley was director, president and chief operating officer at Tesaro, a biotechnology company she co- founded in 2010, focused on the development and global commercialization of oncology therapeutics.

She was executive vice president and cso of the biotechnology company, Abraxis Bioscience, responsible for R&D, Operations, Medical Affairs and Business Development. Elsewhere she was executive vice president of Eisai, with a focus on the global reorganization of its R&D program and building a global oncology strategy. She was also Executive Vice President, as well as cso, responsible for R&D, at MGI PHARMA (MGI) until its acquisition by Eisai in 2008. In addition, she was co-founder, director, president and ceo of ZYCOS prior to its acquisition by MGI in 2004.

Helsinn: Mary Lynne Hedley appointed to board of directors



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram